公开(公告)号：HRP20181740T1

公开(公告)日：2018-12-28

申请号：HRP20181740

申请日：2018-10-23

Applicant: VERTEX PHARMA

Inventor： VERWIJS MARINUS JACOBUS ,  KARKARE RADHIKA ,  MOORE MICHAEL DOUGLAS

IPC: A61K9/20 ,  A61K31/443 ,  A61K31/47 ,  A61K45/06

公开(公告)号：SG10201703452PA

公开(公告)日：2017-06-29

申请号：SG10201703452P

申请日：2013-11-01

Applicant: VERTEX PHARMA

Inventor： VERWIJS MARINUS JACOBUS ,  KARKARE RADHIKA ,  MOORE MICHAEL DOUGLAS

Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.